Companies will start with extraction from stool samples.
ZyGEM and Phthisis Diagnostics have joined forces to develop products for the detection of infectious pathogens in complex samples such as stool, blood, and water. The first target of the collaboration is extraction of pathogen DNA from stool.
The collaboration will harness ZyGEM’s advanced enzymatic nucleic acid extraction technology and Phthisis’ molecular diagnostic expertise to provide solutions for obtaining high-quality DNA from infectious pathogens. ZyGEM’s technology uses a thermophilic enzyme to extract DNA from samples using a single closed-tube system.
The approach significantly reduces the time and cost of DNA extractions while simplifying laboratory workflow, minimizing error, reducing the risk of contamination, ensuring sample integrity, and facilitating extractions from trace amounts, according to the company.
“The ability of ZyGEM’s unique temperature-controlled DNA extraction technology to work well with a wide range of sample types makes it suitable for use with challenging targets with high unmet need,” says Paul Kinnon, CEO of ZyGEM. “We believe the accuracy, simplicity, and ease-of-use of our technology make it an especially good fit with the product focus of Phthisis Diagnostics.
The deal with Phthisis follows a collaboration inked in May, under which ZyGEM agreed to incorporate its technology into Rubicon Genomics’ preanalytical platform designed to improve the performance of DNA and RNA analytical instruments.